Alliance Health Group, UK

alliancehealthgroup.co.uk

Alliance Health Group has a unique approach to healthcare, we put consultants at the heart of the patient pathway. Through our partnerships with major insurers such as VitalityHealth we have worked collaboratively to achieve impressive NPS scores of 57. Alliance Health Group provide healthcare trusts for companies such as Rolls-Royce plc, Mitie and Anglian Water. Our consultants streamline the patient pathway and manage the process from day one, meaning a faster, more clinically focused and a more efficient journey for the patient, saving significant amounts by streamlining pathways to cut out unnecessary financial waste.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BOLD-100 OUTPERFORMS REMDESIVIR HEAD-TO-HEAD IN SARS-COV-2 (COVID-19), THE ONLY HIGHLY POTENT ANTIVIRAL AGENT

PR Newswire | August 18, 2020

news image

Bold Therapeutics, a clinical-stage biopharmaceutical company, recently generated additional data supporting rapid clinical development of BOLD-100 as a novel antiviral. In a series of experiments conducted by Dr. Stephen Barr, Associate Professor in the Department of Microbiology and Immunology at Western University, both BOLD-100 and remdesivir were tested head-to-head in a cytopathic effect assay against a live Wuhan strain of SARS-CoV-2 (COVID-19) in Vero E6 cells. Consistent with prior expe...

Read More

MEDTECH

SPECTRUMX CONFIRMS NEXT STEP IN CLINICAL DEVELOPMENT OF RESPIRATORY DRUG CANDIDATE SPX-001 AFTER MHRA MEETING

SpectrumX | November 25, 2022

news image

SpectrumX, a UK-based healthcare and pharmaceutical company announces that following a constructive scientific advice meeting with the Medicines and Healthcare products Regulatory Agency on Monday, 14th November, the Company is prepared to move forward with the next stage in clinical development of its respiratory drug candidate SPX-001. Per regulatory guidelines, SpectrumX will submit a combined Clinical Trial and Ethics Committee application for a placebo-controlled phase Ib inf...

Read More

MEDICAL

BIOCINA ANNOUNCES OPENING OF NEW GMP PLASMID DNA MANUFACTURING SUITE

BioCina | June 14, 2022

news image

BioCina, a leading contract development and manufacturing organization (CDMO) today announced that the company has expanded its CDMO service offering to include the manufacture of plasmid DNA (pDNA) in a new dedicated GMP suite. The suite is equipped with up to 300 L single use fermentation capacity and suitably scaled downstream processing equipment. To complement GMP manufacturing, a broad range of analytical methods have been developed to support in-process, release and stability testing of p...

Read More

AXON NEUROSCIENCE, A CLINICAL-STAGE BIOTECH COMPANY TO LAUNCH WORLD'S FIRST CROWDFUNDED VACCINE AGAINST COVID-19

COVIDAX | September 19, 2020

news image

AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 – ACvac1. With more than 20 years of experience developing an exceptionally safe and immunogenic peptide vaccine against dementia, in April 2020 Axon announced its plan to develop a novel peptide vaccine agains...

Read More
news image

BOLD-100 OUTPERFORMS REMDESIVIR HEAD-TO-HEAD IN SARS-COV-2 (COVID-19), THE ONLY HIGHLY POTENT ANTIVIRAL AGENT

PR Newswire | August 18, 2020

Bold Therapeutics, a clinical-stage biopharmaceutical company, recently generated additional data supporting rapid clinical development of BOLD-100 as a novel antiviral. In a series of experiments conducted by Dr. Stephen Barr, Associate Professor in the Department of Microbiology and Immunology at Western University, both BOLD-100 and remdesivir were tested head-to-head in a cytopathic effect assay against a live Wuhan strain of SARS-CoV-2 (COVID-19) in Vero E6 cells. Consistent with prior expe...

Read More
news image

MEDTECH

SPECTRUMX CONFIRMS NEXT STEP IN CLINICAL DEVELOPMENT OF RESPIRATORY DRUG CANDIDATE SPX-001 AFTER MHRA MEETING

SpectrumX | November 25, 2022

SpectrumX, a UK-based healthcare and pharmaceutical company announces that following a constructive scientific advice meeting with the Medicines and Healthcare products Regulatory Agency on Monday, 14th November, the Company is prepared to move forward with the next stage in clinical development of its respiratory drug candidate SPX-001. Per regulatory guidelines, SpectrumX will submit a combined Clinical Trial and Ethics Committee application for a placebo-controlled phase Ib inf...

Read More
news image

MEDICAL

BIOCINA ANNOUNCES OPENING OF NEW GMP PLASMID DNA MANUFACTURING SUITE

BioCina | June 14, 2022

BioCina, a leading contract development and manufacturing organization (CDMO) today announced that the company has expanded its CDMO service offering to include the manufacture of plasmid DNA (pDNA) in a new dedicated GMP suite. The suite is equipped with up to 300 L single use fermentation capacity and suitably scaled downstream processing equipment. To complement GMP manufacturing, a broad range of analytical methods have been developed to support in-process, release and stability testing of p...

Read More
news image

AXON NEUROSCIENCE, A CLINICAL-STAGE BIOTECH COMPANY TO LAUNCH WORLD'S FIRST CROWDFUNDED VACCINE AGAINST COVID-19

COVIDAX | September 19, 2020

AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 – ACvac1. With more than 20 years of experience developing an exceptionally safe and immunogenic peptide vaccine against dementia, in April 2020 Axon announced its plan to develop a novel peptide vaccine agains...

Read More